TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04189289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block group
Description: USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an out-plane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
Study: NCT04266678

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise program
Description: Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Description: Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
Study: NCT02898766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrition Formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrition Formula
Study: NCT05274399

Intervention type: OTHER
Intervention: surveys and questionnaires
Description: The data containing the questions determining the relationship between the self-care power and hopelessness of the patients who voluntarily participated in the study were collected through a questionnaire.
Study: NCT01964105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Imaging

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D Imaging
Study: NCT04554407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMAVAC® 100 Sustained Vacuum System
Description: The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
Study: NCT02991261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC001 type I
Description: Treatment type I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC001 type I
Description: Treatment type I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001 type I
Description: Treatment type I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001 type I
Description: Treatment type I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC001 type II
Description: Treatment type II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC001 type II
Description: Treatment type II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001 type II
Description: Treatment type II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001 type II
Description: Treatment type II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference001 type I
Description: Hydrocodone-acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference001 type I
Description: Hydrocodone-acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 type I
Description: Hydrocodone-acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 type I
Description: Hydrocodone-acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference001 type II
Description: Hydrocodone Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference001 type II
Description: Hydrocodone Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 type II
Description: Hydrocodone Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 type II
Description: Hydrocodone Acetaminophen
Study: NCT04622865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
Study: NCT00773552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: 5mg PO Qday x 90 days
Study: NCT03178552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
Study: NCT00773552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tab PO Qday x 90 days
Study: NCT02197221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib-Melphalan
Description: Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be administered on day -2. The PBSC will be injected on day 0.
Study: NCT01850303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: 4 cycles of carboplatin-paclitaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Induction chemotherapy
Description: 4 cycles of carboplatin-paclitaxel
Study: NCT01508156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 liquid suspension (1 - 100 mg) taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 liquid suspension (1 - 100 mg) taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo liquid suspension matching IDX719 taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo liquid suspension matching IDX719 taken by mouth.
Study: NCT02836197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training
Description: The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
Study: NCT03811249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisAbility™ Micro Insert
Description: No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
Study: NCT00124566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m\^2 per day, once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
Study: NCT04049890

Intervention type: OTHER
Intervention: FAI-O
Description: Administration of Family Adjustment Inventory in the version Only-child

Intervention type: OTHER
Intervention: FAI-S
Description: Administration of Family Adjustment Inventory in the version Sibling

Intervention type: OTHER
Intervention: Personal Data Questionnaire
Description: This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year

Intervention type: OTHER
Intervention: Personal Data Questionnaire
Description: This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
Study: NCT00802633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stapling device during radical cystectomy
Description: Hemostasis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure tissue sealing device
Description: Efficacy of tissue sealing device during hemostasis
Study: NCT02133352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
Study: NCT00206622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Climara PRO (Estradiol / Levonorgestrel transdermal)
Description: 2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menostar (Estradiol transdermal)
Description: 1mg 17 Beta-estradiol transdermal patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal
Description: Placebo
Study: NCT01208259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Study: NCT01890018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle tracking
Description: All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle tracking
Description: All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Pill Bottle tracking
Description: All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle tracking
Description: All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Messaging
Description: Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Messaging
Description: Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Influence
Description: Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Influence
Description: Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
Study: NCT01755611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg
Description: Reference product
Study: NCT01676259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siG12D-LODER
Description: The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+nab-Paclitaxel
Description: Gemcitabine+nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Folfirinox or modified Folfirinox
Study: NCT00595387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
Study: NCT00789828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
Study: NCT01318733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 gel 0.5%
Description: In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
Study: NCT02053571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS with 3D Overlay
Study: NCT01873079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: No PPI or other study medication given
Study: NCT03036995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
Study: NCT02267850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic Appliance Treatment
Description: Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fixed Orthodontic Appliance Treatment
Description: Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Patients carry out daily OrthoPulse™ treatments at home.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-Functional OrthoPulse™
Description: Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
Study: NCT01039285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf
Description: 2.5 ml/kg instilled in the trachea

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Air
Description: 2.5ml/kg of Air will be instilled in the trachea
Study: NCT03012815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin administered as a taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzodiazepines
Description: Benzodiazepines administered using a symptoms triggered protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
Study: NCT05003128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED screen (InnoLux, Taiwan)
Description: Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
Study: NCT01162395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3514
Description: Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
Study: NCT00185328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/DRSP (Angeliq, BAY86-4891)
Description: 1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
Study: NCT01218737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin and 1.0% prednisolone acetate association
Description: Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isolated 0.3% gatifloxacin and 1.0% prednisolone acetate
Description: Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15.
Study: NCT00762983

Intervention type: DRUG
Intervention: loratadine
Description: Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to \< 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified.
Study: NCT03178552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
Study: NCT04323436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Concentrate for solution for infusion
Study: NCT00973037

Intervention type: DRUG
Intervention: Tamoxifen
Description: Tamoxifen 20mg qd
Study: NCT02856815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \~ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour
Study: NCT04323436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Film-coated tablet
Study: NCT02077959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pidilizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02731833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: 0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium monofluorophosphate
Description: 0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Study: NCT01880645

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine Needle Aspiration (FNA)
Description: If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast Surgery + Lymph Node Removal
Description: Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).